Congress Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $73.7M | Buy |
647,941
+5,229
| +0.8% | +$594K | 0.51% | 84 |
|
|
2025
Q1 | $67.6M | Buy |
642,712
+21,230
| +3% | +$2.23M | 0.51% | 78 |
|
|
2024
Q4 | $66.6M | Buy |
621,482
+17,444
| +3% | +$1.87M | 0.45% | 87 |
|
|
2024
Q3 | $60.5M | Buy |
604,038
+17,414
| +3% | +$1.74M | 0.41% | 93 |
|
|
2024
Q2 | $49.4M | Buy |
+586,624
| New | +$49.4M | 0.35% | 96 |
|
|
2020
Q4 | – | Sell |
-51,897
| Closed | -$3.09M | – | 350 |
|
|
2020
Q3 | $3.09M | Buy |
51,897
+2,289
| +5% | +$136K | 0.03% | 204 |
|
|
2020
Q2 | $3.46M | Buy |
49,608
+1,050
| +2% | +$73.3K | 0.04% | 189 |
|
|
2020
Q1 | $2.2M | Buy |
48,558
+17,974
| +59% | +$815K | 0.03% | 211 |
|
|
2019
Q4 | $1.99M | Sell |
30,584
-10,393
| -25% | -$676K | 0.02% | 252 |
|
|
2019
Q3 | $2.55M | Buy |
40,977
+2,560
| +7% | +$159K | 0.03% | 249 |
|
|
2019
Q2 | $2.74M | Buy |
38,417
+2,588
| +7% | +$184K | 0.03% | 252 |
|
|
2019
Q1 | $2.81M | Buy |
35,829
+1,536
| +4% | +$120K | 0.04% | 241 |
|
|
2018
Q4 | $2.9M | Sell |
34,293
-72
| -0.2% | -$6.1K | 0.04% | 232 |
|
|
2018
Q3 | $5.89M | Sell |
34,365
-653
| -2% | -$112K | 0.08% | 164 |
|
|
2018
Q2 | $4.53M | Buy |
35,018
+1,623
| +5% | +$210K | 0.06% | 190 |
|
|
2018
Q1 | $3.44M | Buy |
33,395
+3,530
| +12% | +$364K | 0.05% | 219 |
|
|
2017
Q4 | $2.55M | Buy |
29,865
+6,052
| +25% | +$517K | 0.04% | 236 |
|
|
2017
Q3 | $2.02M | Buy |
23,813
+11,572
| +95% | +$983K | 0.03% | 257 |
|
|
2017
Q2 | $927K | Buy |
12,241
+1,977
| +19% | +$150K | 0.02% | 201 |
|
|
2017
Q1 | $678K | Buy |
10,264
+3,076
| +43% | +$203K | 0.01% | 214 |
|
|
2016
Q4 | $456K | Buy |
+7,188
| New | +$456K | 0.01% | 222 |
|